Literature DB >> 24792772

Evaluation of pre-analytical variables in a commercial thrombin generation assay.

Susan E Rodgers1, Amanda Wong2, Reanuga D Gopal3, Brian J Dale2, Elizabeth M Duncan3, Simon J McRae4.   

Abstract

BACKGROUND: There is minimal data on the influence of pre-analytical variables on the use of calibrated automated thrombography (CAT), to measure thrombin generation.
OBJECTIVES: To evaluate the impact of centrifugation methods, time after collection, and contact activation inhibition on the CAT assay performed using two commercial reagents. METHODS AND
RESULTS: Six different methods of plasma separation were examined. Thrombin generation triggered by a 5 pM tissue factor reagent was not greatly affected by plasma separation method, with similar results obtained with all methods apart from single centrifugation and membrane filtration. Membrane filtration increased APTT and is not recommended. Extended double centrifugation at higher speed was required to minimise the impact of residual phospholipid with 1 pM tissue factor trigger, particularly with inhibition of contact activation. The effect of a delay of up to 24 hours in preparing plasma was assessed. No significant difference in results was observed among samples processed between 0.5 and 6 hours after blood collection into plastic Vacuette® tubes. The presence or absence of corn trypsin inhibitor had a significant impact on all parameters with 1 pM tissue factor trigger, with minor differences seen on Peak and ttPeak results using 5 pM tissue factor.
CONCLUSIONS: The impact of pre-analytical variables on thrombin generation results is dependent on the concentration of tissue factor in the trigger reagent used. Results with 1 pM tissue factor are particularly sensitive to centrifugation method and contact activation, and standardisation is required to allow large collaborative studies to be performed.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  blood coagulation tests; centrifugation; corn trypsin inhibitor; thrombin generation assay; time factors

Mesh:

Substances:

Year:  2014        PMID: 24792772     DOI: 10.1016/j.thromres.2014.04.010

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  5 in total

1.  Assessment of the analytical performances and sample stability on ST Genesia system using the STG-DrugScreen application.

Authors:  Jonathan Douxfils; Laure Morimont; Céline Bouvy; Marie de Saint-Hubert; Bérangère Devalet; Célia Devroye; Anne-Sophie Dincq; Jean-Michel Dogné; Maïté Guldenpfennig; Justine Baudar; Anne-Sophie Larock; Sarah Lessire; François Mullier
Journal:  J Thromb Haemost       Date:  2019-05-31       Impact factor: 5.824

2.  Comparison of Acquired Activated Protein C Resistance, Using the CAT and ST-Genesia® Analysers and Three Thrombin Generation Methods, in APS and SLE Patients.

Authors:  Maria Efthymiou; Philip J Lane; David Isenberg; Hannah Cohen; Ian J Mackie
Journal:  J Clin Med       Date:  2021-12-23       Impact factor: 4.241

3.  Analytical performance of the endogenous thrombin potential-based activated protein C resistance assay on the automated ST Genesia system.

Authors:  Laure Morimont; Charline Leclercq; Marie Didembourg; Émilie De Gottal; Audrey Carlo; Ulysse Gaspard; Jean-Michel Dogné; Jonathan Douxfils
Journal:  Res Pract Thromb Haemost       Date:  2022-04-07

4.  Thrombin generation measurement using the ST Genesia Thrombin Generation System in a cohort of healthy adults: Normal values and variability.

Authors:  Sara Calzavarini; Justine Brodard; Claudia Quarroz; Livia Maire; Raphael Nützi; Jovana Jankovic; Laura C Rotondo; Evelyne Giabbani; Georg Martin Fiedler; Michael Nagler; Anne Angelillo-Scherrer
Journal:  Res Pract Thromb Haemost       Date:  2019-07-18

5.  Studies on hemostasis in COVID-19 deserve careful reporting of the laboratory methods, their significance, and their limitations.

Authors:  Michael Hardy; Jonathan Douxfils; Marion Bareille; Sarah Lessire; Isabelle Gouin-Thibault; Pierre Fontana; Thomas Lecompte; François Mullier
Journal:  J Thromb Haemost       Date:  2020-11       Impact factor: 16.036

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.